Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significance of Lipid-Derived Reactive Aldehyde-Specific Immune Complexes in Systemic Lupus Erythematosus.

PloS one·2016
Same author

Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus.

Clinica chimica acta; international journal of clinical chemistry·2016
Same author

Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to β2 Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration.

American journal of clinical pathology·2016
Same author

Pathophysiology of the antiphospholipid antibody syndrome.

Auto- immunity highlights·2015
Same author

Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.

Blood·2014
Same author

Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis.

Rheumatology (Oxford, England)·2014

Related Experiment Video

Updated: May 13, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Pathophysiological mechanisms in antiphospholipid syndrome.

Brock E Harper1, Rohan Wills, Silvia S Pierangeli

  • 1Department of Internal Medicine, Division of Rheumatology, University of texas medical branch, Galveston, TX, USA.

International Journal of Clinical Rheumatology
|March 15, 2013
PubMed
Summary

Antiphospholipid syndrome involves thrombosis and fetal loss due to antiphospholipid (aPL) antibodies targeting β2-glycoprotein I (β2GPI). Understanding β2GPI's role reveals new therapeutic strategies for this autoimmune disorder.

Keywords:
annexinanti-β2-glycoprotein I antibodyantiphospholipid antibodiesantiphospholipid syndromeendothelial cell activationpathogenesisplatelet activationpregnancy lossthrombosistreatment

More Related Videos

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Related Experiment Videos

Last Updated: May 13, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Area of Science:

  • Immunology
  • Hematology
  • Reproductive Medicine

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by blood clots (thrombosis) and pregnancy complications.
  • Antiphospholipid (aPL) antibodies are key diagnostic markers for APS.
  • β2-glycoprotein I (β2GPI) is identified as the primary target antigen for aPL antibodies.

Purpose of the Study:

  • To summarize recent findings on the role of β2GPI in APS.
  • To explore the interactions between aPL antibodies, β2GPI, and cellular components.
  • To examine the molecular mechanisms leading to thrombosis and fetal loss in APS and discuss novel therapeutic avenues.

Main Methods:

  • Review of current literature on antiphospholipid syndrome and β2GPI.
  • Analysis of molecular interactions between aPL antibodies, β2GPI, and target cells (endothelial cells, monocytes, platelets, trophoblasts).
  • Examination of pathogenic pathways contributing to thrombosis and fetal loss.

Main Results:

  • β2GPI mediates the binding of aPL antibodies to various cell types.
  • This interaction induces prothrombotic and pro-inflammatory changes.
  • Pathogenic mechanisms leading to thrombosis and recurrent fetal loss in APS are elucidated.

Conclusions:

  • β2GPI plays a critical role in the pathogenesis of antiphospholipid syndrome.
  • Understanding these molecular interactions provides a basis for developing targeted therapies.
  • New therapeutic strategies for APS are emerging based on these insights.